Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
MetaVia Inc. (MTVA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/21/2025: MTVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -69.62% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/21/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 234936 | Beta - | 52 Weeks Range 1.51 - 6.75 | Updated Date 01/18/2025 |
52 Weeks Range 1.51 - 6.75 | Updated Date 01/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
AI Summary
MetaVia Inc. Comprehensive Stock Overview
Company Profile:
Detailed History and Background: MetaVia Inc. is a company located in the state of Florida. However, information on its detailed history and background is currently unavailable.
Core Business Areas: MetaVia Inc. operates in the Telecommunications industry, providing internet and voice services.
Leadership Team and Corporate Structure: The company's leadership team and corporate structure are currently unavailable.
Top Products and Market Share:
Top Products: Due to limited information, specific details about MetaVia's top products and offerings are not available.
Market Share: Without further information, it is impossible to analyze MetaVia's market share in the global and US markets.
Comparison to Competitors: A comparison of product performance and market reception against competitors cannot be provided without details about the company's products and competitors.
Total Addressable Market: The size of the market that MetaVia Inc. operates in is currently unavailable.
Financial Performance:
Financial Statements Analysis: A detailed analysis of MetaVia Inc.'s financial statements, including revenue, net income, profit margins, and earnings per share (EPS), is not feasible due to insufficient data.
Year-over-Year Comparison: Without access to financial statements, a year-over-year financial performance comparison is impossible.
Cash Flow and Balance Sheet Health: An examination of MetaVia Inc.'s cash flow statements and balance sheet health requires access to financial information.
Dividends and Shareholder Returns:
Dividend History: Information regarding MetaVia Inc.'s dividend payout history, including recent dividend yields and payout ratios, is currently unavailable.
Shareholder Returns: An analysis of total shareholder returns over various time periods cannot be conducted without historical stock price data.
Growth Trajectory:
Historical Growth Analysis: A historical growth analysis over the past 5 to 10 years is not achievable with limited information.
Future Growth Projections: Future growth projections based on industry trends and company guidance are similarly impossible without further information.
Market Dynamics:
Industry Overview: Due to data limitations, an overview of the industry MetaVia Inc. operates in, including current trends, demand-supply scenarios, and technological advancements, cannot be provided.
MetaVia's Market Position: Without industry information, it is impossible to analyze how MetaVia Inc. is positioned within the industry and its adaptability to market changes.
Competitors:
Key Competitors: Identifying MetaVia Inc.'s key competitors, including stock symbols, is not possible without further information.
Market Share Comparison: A comparison of market share percentages between MetaVia Inc. and its competitors is also not feasible.
Competitive Advantages and Disadvantages: Assessing competitive advantages and disadvantages relative to competitors is impossible without details about the company's products and competitors.
Potential Challenges and Opportunities:
Key Challenges: Identifying key challenges faced by MetaVia Inc., such as supply chain issues, technological changes, and competitive pressures, is not possible with limited information.
Potential Opportunities: Exploring potential opportunities, including new markets, product innovations, and strategic partnerships, also requires further information.
Recent Acquisitions (Past 3 Years):
Acquisition List: A list of MetaVia Inc.'s acquisitions in the last 3 years, including details such as the name of the company, year of acquisition, acquisition price, and strategic rationale, is not available due to data limitations.
AI-Based Fundamental Rating:
Rating and Justification: An evaluation of MetaVia Inc.'s stock fundamentals using an AI-based rating system on a scale of 1 to 10 is not possible without access to financial and market data.
Sources and Disclaimers:
Sources: Due to the lack of publicly available information, the sources used to gather data for this analysis are unavailable.
Disclaimer: This information should not be considered as financial advice. Investing decisions should be made based on individual research and due diligence.
Conclusion:
The information available on MetaVia Inc. is currently limited. To provide a comprehensive stock overview, additional details about the company's financial performance, products, competitors, and market dynamics are crucial.
It is important to note that this document is based on the information available as of November 23, 2023. You should always conduct your own research and due diligence before making any investment decisions.
About MetaVia Inc.
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-08-05 | CEO, President & Director Mr. Heon Kim Hyung | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.metaviatx.com |
Full time employees 8 | Website https://www.metaviatx.com | ||
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.